There's no denying that Mad Money host Jim Cramer is entertaining, popular, and passionate. On many occasions, he's even right. So he's smart, funny, and the closest thing to a stock market rock star -- but is he smarter than you?

Cramming for Cramer
The Fool's free investing community, Motley Fool CAPS, aggregates the opinion of more than 145,000 members to assign ratings for each stock's likelihood of outperforming or underperforming the market.

Below, we look at some top stocks that Cramer picked and panned during last week's "lightning rounds," and compare them to how the CAPS community sees their future.

Stock

Lightning Round Show Date

Cramer's Rating 

CAPS Rating (out of 5)

Citigroup

Monday

Bearish

***

Akamai Technologies (NASDAQ:AKAM)

Monday

Bullish

*****

Activision Blizzard (NASDAQ:ATVI)

Tuesday

Bearish

*****

Home Depot (NYSE:HD)

Tuesday

Bullish

**

MannKind

Wednesday

Bearish

**

JDS Uniphase

Wednesday

Bullish

***

RF Micro Devices (NASDAQ:RFMD)

Thursday

Bearish

****

salesforce.com (NYSE:CRM)

Thursday

Bullish

*

Dendreon (NASDAQ:DNDN)

Friday

Bullish

**

Boeing (NYSE:BA)

Friday

Bullish

***

Cramer says
Biotech investors are all too familiar with the rocky run Dendreon has had over the past few years, but Cramer says that if the company has developed the silver bullet for cancer, then investors will be looking back on this time fondly.

I think ... this is one of those companies, a binary company ... if they have the ultimate vaccine for cancer, you know this thing is going much higher. ... In the interim, I think that you stay with it; let's see ... because this thing could go up 10 points on good news ... so I think you are OK. ... [L]et's just stay long with it right now.

CAPS says
The CAPS community has been far more circumspect in its view of the biotech. While Dendreon has convinced 78% of the CAPS members rating that it will outperform the markets, among adherents it generates strong passions about its potential. Others take a more reasoned approach in believing that Provenge -- with its strong likelihood of success before the FDA -- will offer a good return on investment over the long haul. Says CAPS member jonnycolfax: "While many projections for the upper limit of this stock are unreasonably high, FDA approval is highly likely and the sales potential for Provenge is strong. I believe they will see revenue generation in late 2010 and steadily grow over the next several years."

This Fool says
The caveat to Dendreon's cancer elixir is whether the FDA will find new reasons to deny it. After the biotech ran into headwinds from the regulatory agency in 2007, it met the challenges posed through subsequent clinical trials, and now it goes before the board again in May. The biggest hurdle before it seems to now be on the manufacturing side, where it needs to prove it can duplicate its results on a large scale.

I don't think Dendreon is too concerned about a failure here, and I suspect it's expecting those headwinds to turn into tailwinds. It recently priced an offering to realize around $350 million so it can accelerate construction of manufacturing facilities around the country, as well as hire people to market Provenge. It is getting ready to hit the ground running.

Shares of the stock have traded in a fairly tight range between $25 and $30 over the past quarter, and there's nothing before the May FDA decision that ought to cause it to run one way or the other. Investors who believe in Dendreon's ability to get past these last obstacles would probably do well to accumulate shares here, since approval will undoubtedly cause the stock to spike, and it may never look back again. I'm guessing they're leaving nothing to chance in ensuring that this will be a smooth move to higher plateaus.

Your say
CAPS members may stand with Jim Cramer or on opposite sides of the field. But our investor-intelligence community is more than what some All-Stars think, even if they are TV personalities. What do you think? Is Cramer right, or is he off his rocker? Drop by Dendreon's CAPS page and tell us what its future looks like to you.

Motley Fool CAPS is a great place to start your own research on these stocks. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made -- all from a stock's CAPS page. Best of all, CAPS is free.

Home Depot is a Motley Fool Inside Value recommendation. Akamai Technologies and Salesforce.com are Motley Fool Rule Breakers picks. Activision Blizzard is a Motley Fool Stock Advisor recommendation. Motley Fool Options recommends a synthetic long position on Activision Blizzard. The Fool owns shares of Activision Blizzard. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Rich Duprey has no financial position in any of the stocks mentioned in this article. You can see his holdings. Check out The Motley Fool's disclosure policy.